Coccidioidomycosis (Valley Fever) is difficult to diagnosis due to lack of awareness and symptoms imitating many other respiratory infections.
Valley Fever is said to cause nearly 30% of all community acquired pneumonia (CAP) cases, but only about 15,000 cases are reported each year in the US.1 IMMY’s simple, rapid LFA allows for better care and stewardship for patients.
SERUM | Positive % Agreement | Negative % Agreement | PPV | NPV |
---|---|---|---|---|
Competitor EIA | 93% | 99% | 94% | 99% |
Competitor EIA + ID | 92% | 99% | 94% | 99% |
When tested against a competitor’s EIA and ID results, the CTA LFA showed high diagnostic performance in 908 serum specimens.
The CTA LFA agreed with 93% of the competitor’s EIA positive test results, and 99% of their negative test results. When compared to both the competitor’s EIA and ID results, the CTA LFA agreed with 92% of their positive results and 99% of their negative results.
Coccidioides Antibody LFA | 50 tests | CTA2003 |
---|